Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

by | Aug 7, 2026 | Clinical Trials | 0 comments

​ Conditions: Triple-Negative Breast Cancer (TNBC)

Interventions: Drug: Retlirafusp alfa+Nab-paclitaxel:; Drug: Retlirafusp alfa+Fluzoparib; Drug: Retlirafusp alfa+TP-AC; Drug: Retlirafusp alfa+Fluzoparib

Sponsors: Harbin Medical University

Not yet recruiting Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: Drug: Retlirafusp alfa+Nab-paclitaxel:; Drug: Retlirafusp alfa+Fluzoparib; Drug: Retlirafusp alfa+TP-AC; Drug: Retlirafusp alfa+Fluzoparib
Sponsors: Harbin Medical University
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *